JP2024517871A5 - - Google Patents
Info
- Publication number
- JP2024517871A5 JP2024517871A5 JP2023568310A JP2023568310A JP2024517871A5 JP 2024517871 A5 JP2024517871 A5 JP 2024517871A5 JP 2023568310 A JP2023568310 A JP 2023568310A JP 2023568310 A JP2023568310 A JP 2023568310A JP 2024517871 A5 JP2024517871 A5 JP 2024517871A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- optionally
- amino acid
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185941P | 2021-05-07 | 2021-05-07 | |
| US63/185,941 | 2021-05-07 | ||
| US202263313087P | 2022-02-23 | 2022-02-23 | |
| US63/313,087 | 2022-02-23 | ||
| PCT/US2022/072121 WO2022236292A2 (en) | 2021-05-07 | 2022-05-05 | Compositions and methods comprising protease-activated therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517871A JP2024517871A (ja) | 2024-04-23 |
| JP2024517871A5 true JP2024517871A5 (enExample) | 2025-05-15 |
Family
ID=83932456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568310A Pending JP2024517871A (ja) | 2021-05-07 | 2022-05-05 | プロテアーゼ活性化治療剤を含む組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240228586A1 (enExample) |
| EP (1) | EP4333873A4 (enExample) |
| JP (1) | JP2024517871A (enExample) |
| WO (1) | WO2022236292A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022001320A2 (pt) * | 2019-07-25 | 2022-04-12 | Univ Chicago | Composições e métodos compreendendo agentes terapêuticos ativados por protease |
| WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| EP4704979A1 (en) * | 2023-01-20 | 2026-03-11 | Boehringer Ingelheim International GmbH | Il-12 fc fusion proteins |
| WO2025242835A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) * | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969027B2 (en) * | 2008-03-03 | 2015-03-03 | Kansas State University Research Foundation | Protease assay |
| WO2016023040A1 (en) * | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| BR112022001320A2 (pt) * | 2019-07-25 | 2022-04-12 | Univ Chicago | Composições e métodos compreendendo agentes terapêuticos ativados por protease |
| AU2020353235A1 (en) * | 2019-09-28 | 2022-03-31 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
-
2022
- 2022-05-05 US US18/559,180 patent/US20240228586A1/en active Pending
- 2022-05-05 WO PCT/US2022/072121 patent/WO2022236292A2/en not_active Ceased
- 2022-05-05 EP EP22799803.6A patent/EP4333873A4/en active Pending
- 2022-05-05 JP JP2023568310A patent/JP2024517871A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542886A5 (enExample) | ||
| JP2024517871A5 (enExample) | ||
| US9796777B2 (en) | Methods of treating malignant tumors | |
| CN113226472A (zh) | 双免疫细胞衔接物 | |
| JP7848182B2 (ja) | 改善された抗原結合受容体 | |
| CA2289912A1 (en) | Human receptor proteins; related reagents and methods | |
| CA2386463A1 (en) | April receptor (bcma) and uses thereof | |
| WO2021092075A1 (en) | IL-2RβγC BINDING COMPOUNDS | |
| US20220098274A1 (en) | Engineered pd-1 variants | |
| JP2020508691A5 (enExample) | ||
| CN110662560A (zh) | 改进的抗原结合受体 | |
| CN110461360A (zh) | 改进的抗原结合受体形式 | |
| JP2023547447A (ja) | 改良型抗原結合受容体 | |
| KR20220093323A (ko) | HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료 | |
| KR20240111753A (ko) | 개선된 항원 결합 수용체 | |
| US20260103528A1 (en) | Nanobodies that bind to gprc5d and uses thereof | |
| KR101974583B1 (ko) | 링커 폴리펩티드 및 이를 이용한 표적 물질 분석 방법 | |
| WO2025125378A1 (en) | Novel serum albumin-binding fusion proteins | |
| JP2022535816A5 (enExample) | ||
| WO2024003393A1 (en) | Fusion proteins with half life extending domains | |
| CN119731199A (zh) | 工程化的白细胞介素-2受体β降低结合的激动剂 | |
| TWI921762B (zh) | 結合至ｇｐｒｃ５ｄ的奈米抗體及其用途 | |
| JP2025527694A5 (enExample) | ||
| WO2025080338A1 (en) | Cell-surface anchored cytokine therapy | |
| EA051364B1 (ru) | Улучшенные антигенсвязывающие рецепторы |